Regeneron Predicts Impending Biosimilar Lucentis Impact On Eylea Brand
Samsung Bioepis Tipped For US Ranibizumab Biosimilar Approval Soon
Regeneron Pharmaceuticals has spoken out on the implication of impending competition to Lucentis for its rival product Eylea, as the market for biosimilar Lucentis looks to form by the close of this year.
You may also be interested in...
Viatris provided several key updates for its biosimilar pipeline during the company’s Q3 earnings call, including for its biosimilar Eylea and Botox candidates, as well as disclosing another key early-stage asset.
The US FDA has accepted for review the CHS-201 Lucentis biosimilar product developed by Formycon/Bioeq that is to be sold in the US by Coherus BioSciences, shortly after approving the first ranibizumab biosimilar to treat wet age-related macular degeneration.
Samsung Bioepis has celebrated the FDA’s first ever approval of an ophthalmic biosimilar with its endorsement of the firm’s Byooviz ranibizumab rival to Lucentis. The firm has also signaled a surprising expected launch date in the US, as well as offering expectations for launch in Europe where the biosimilar was also recently approved.